MIEBO (perfluorohexyloctane) ophthalmic solution, identified by NDC number 0169-0070-10, is used to treat signs and symptoms of dry eye disease [1].
What is MIEBO used for?
MIEBO is indicated for the treatment of the signs and symptoms of dry eye disease [1]. It works by reducing evaporation from the tear film [2].
How does MIEBO work?
MIEBO contains perfluorohexyloctane, a molecule that forms a lipid layer on the surface of the eye [2]. This layer helps to prevent tear evaporation by creating a barrier that spreads across the ocular surface and stabilizes the tear film [3][4]. Unlike traditional lipid-based eye drops, MIEBO's chemical structure allows it to spread rapidly and evenly without requiring blinking to distribute [4].
What is the difference between MIEBO and other dry eye treatments?
MIEBO is a non-aqueous formulation, meaning it does not contain water [2]. This differs from many artificial tear products, which are water-based. The absence of water allows MIEBO to more effectively reduce tear evaporation [3]. Its unique chemical properties also enable it to spread quickly across the eye's surface upon instillation, stabilizing the tear film [4].
When does MIEBO's patent protection expire?
Information regarding the specific patent expiry dates for MIEBO is not publicly available in the provided context. DrugPatentWatch.com is a resource that tracks drug patents and exclusivity periods [5].
Who manufactures MIEBO?
MIEBO is manufactured by Bausch + Lomb [1].
What are the potential side effects of MIEBO?
The most common side effect reported with MIEBO is blurred vision upon instillation, which typically resolves quickly [1].
What clinical data supports MIEBO's effectiveness?
Clinical trials have demonstrated that MIEBO significantly reduces tear evaporation and improves ocular surface staining in patients with dry eye disease [3]. Studies have shown a rapid and sustained reduction in tear evaporation rates after MIEBO administration [4].
How is MIEBO administered?
MIEBO is administered as a topical ophthalmic solution [1]. Patients typically instill one drop in each eye as needed [1].
Are there any alternatives to MIEBO for dry eye disease?
Alternative treatments for dry eye disease include artificial tears (various formulations), prescription eye drops like cyclosporine or lifitegrast, punctal plugs, and lifestyle modifications [6]. The choice of treatment depends on the specific cause and severity of the dry eye [6].
What is the pricing or insurance coverage for MIEBO?
Specific pricing information or details on insurance coverage for MIEBO are not available in the provided context.
What regulatory approvals does MIEBO have?
MIEBO is approved by the U.S. Food and Drug Administration (FDA) for the treatment of the signs and symptoms of dry eye disease [1].
Sources:
[1] https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e67e0546-6736-4439-8828-6505e8049277
[2] https://www.drugpatentwatch.com/blogs/news/understanding-miebo-perfluorohexyloctane-ophthalmic-solution
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282254
[4] https://www.dovepress.com/perfluorohexyloctane-an-innovative-option-for-evaporative-dry-eye-dis--peerreview
[5] https://www.drugpatentwatch.com/
[6] https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/dry-eye